Job description
Delivers compliant, non-promotional education to caregivers, patients, residential staff, and healthcare professionals on Prader-Willi syndrome (PWS) and Soleno's approved therapy. Supports the commercial strategy by enhancing disease understanding, supporting treatment adherence, and fostering informed engagement across the PWS community.
Company
Healthcare
Soleno Therapeutics is a biopharmaceutical company dedicated to developing innovative therapies for rare diseases, with a particular focus on Prader-Willi syndrome. In March 2025, the company secured FDA approval for its first and only treatment targeting hyperphagia in PWS, marking a significant milestone in addressing a critical unmet medical need. Leveraging a rigorous scientific approach alongside strong advocacy and community engagement, Soleno blends cutting-edge research with patient-centric values to deliver impactful solutions. The organization fosters a collaborative culture that empowers scientists, clinicians, and patients to work together toward transformative health outcomes.